Shawn Cross, Chief Financial Officer of Pacira BioSciences, Inc. (NASDAQ:PCRX), filed a Form 4 on November 17, 2026, disclosing the disposition of all directly held common stock, restricted stock units, and stock options in connection with the consummation of the company's merger with Viatris Inc.

Key Highlights

  • Merger completed November 17, 2026: Peach Purchaser Sub Inc. merged with and into Pacira BioSciences, with Pacira continuing as a wholly owned subsidiary of Viatris Inc.
  • Offer price of $36.50 per share: Each share of Pacira common stock was converted into the right to receive $36.50, net of applicable withholding taxes and without interest.
  • 9,210 shares disposed via transaction code U: These shares were disposed of pursuant to the cash tender offer at $36.50 per share, reducing Cross's direct holdings from 86,591 shares.
  • 86,591 shares disposed via transaction code D: The remaining directly held shares were disposed of at the merger's effective time at $36.50, leaving Cross with zero directly held common shares.
  • RSUs canceled and converted to cash: All outstanding RSU awards, whether vested or unvested, were canceled at the effective time and converted into the right to receive cash equal to the number of underlying shares multiplied by $36.50, subject to applicable tax withholdings.
  • Stock option with $16.45 exercise price canceled: A stock option to purchase 150,000 shares of common stock, exercisable at $16.45 and expiring 11/04/2034, was disposed of; because its exercise price was below the $36.50 offer price, it was converted into the right to receive cash equal to the spread per share, subject to applicable tax withholdings.
  • Post-transaction beneficial ownership is zero: Following all reported transactions, Cross's directly held beneficial ownership of Pacira common stock stands at 0 shares.

Pacira BioSciences CFO Holdings Zeroed Out at Viatris Merger Effective Time

According to the filing, the transactions reported by Shawn Cross on November 17, 2026, all stem from the Agreement and Plan of Merger dated October 8, 2026, among Pacira BioSciences, Inc., Viatris Inc., and Peach Purchaser Sub Inc. The filing states that at the effective time of the merger on November 17, 2026, Peach Purchaser Sub Inc. merged with and into Pacira BioSciences, with Pacira surviving as a wholly owned subsidiary of Viatris.

The filing discloses two separate common stock dispositions. First, 9,210 shares were disposed of under transaction code U, described as pursuant to the tender offer, at a price of $36.50, reducing Cross's holdings to 86,591 shares. Second, those remaining 86,591 shares were disposed of under transaction code D at the same $36.50 price, leaving Cross with zero directly held shares following the transactions. The filing attributes both dispositions to the merger's conversion of each outstanding share "into the right to receive the Offer Price."

With respect to equity awards, the filing states that all outstanding RSU awards held by Cross, whether vested or unvested, were canceled at the effective time and converted into the right to receive a cash amount based on the total number of underlying shares multiplied by $36.50, subject to applicable withholdings. A stock option to purchase 150,000 shares at an exercise price of $16.45, with an expiration date of November 4, 2034, was also canceled; the filing notes that because its per-share exercise price was below the offer price, it was converted into the right to receive cash equal to the excess of $36.50 over $16.45 per share, subject to withholdings. The filing further notes that any option with a per-share exercise price greater than or equal to $36.50 was canceled with no consideration payable.

What Was Disclosed

Pacira BioSciences CFO Shawn Cross reported the disposition of all directly held common shares, RSUs, and a stock option on November 17, 2026, the effective time of the company's merger with Viatris Inc., with each security converted to cash at $36.50 per share or on a spread basis.